NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/16/2026
Back to search
Official data from USPTO
INOVIQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000097427897Class
1, 5, 10, 42, 44
Filing
97427897
Registration
8300033
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
06/16/2026
Trademark type
Combined
Nice classes
1, 5, 10, 42, 44
Filing date
05/25/2022
Registration date
06/16/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2026
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
Notting Hill, VIC, AU
Examiner
BRUNDAGE, DAVID WILLIAM
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "INOVIQ" to the right of a design of three concentric rings of dots.
Holders and representatives
Holders
INOVIQ Limited
Representatives
Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological reagents for scientific and research use for molecular targets for drug and vaccine development; reagents for medical research applications; reagents for medical research applicationsmolecular targets for drug and vaccine development; biological reagents for use in molecular biology for research purposes; reagents for medical diagnosis research applications
Class 5
Pharmaceuticalbiotechnology and medical preparations and substances for the preventiondiagnosis or treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases; pharmaceuticalbiotechnology and medical preparations and substances for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical purposesextracellular vesiclesRNAprotein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies or exosomes; immunological antibodies for medical use; biological preparations for the treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases for medical purposes; biological preparations for the treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases for pharmaceutical purposes; biological substances for the treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing monoclonal antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancerviral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparationsreagentspharmaceutical and biochemical anti-cancer substancesproducts for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseasestesting materialsdiagnostic test stripsimmunoassaysPCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposesdiagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes; diagnostic preparations and reagents for medical purposesdiagnostic reagents for in-vitro use for medical purposesreagents for in-vitro laboratory use for medical purposesreagents for use in diagnostic tests for medical purposesdiagnostic reagents for medical use for sale in kit form; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical purposes; pharmaceuticalbiotechnology and medical preparations and substances for medical useimmunotherapeutic agents for the treatment of cancer; nucleic acid substances for use in genetic probe assay kits for medical use; preparations for the treatmentreconstruction and repair of antibodiesbiological preparations for pharmaceutical purposes
Class 10
Biotechnology medical apparatus for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseases; medical diagnostic apparatus and instruments for testing biofluidsplasmaserumsalivaurine and cell cultures for sale in kit form; biotechnology medical apparatusmedical apparatus for the capture of extracellular vesicles
Class 42
Scientific researchclinical researchdevelopmentadvisory and consultancy services in relation to antibody production; vaccine screeningin the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; providing diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposesresearch services relating to diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; diagnostic and research services and screening in the nature of research services in the field of diagnostic preparations; preparation of reports relating to medicalscientific and technical research; provision of information relating to medicalscientific and technical research; research and development of products; research and development of productsnew therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of productsextracellular vesicle-based diagnostic productsextracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell lineculturing of cells for others for scientific research purposes
Class 44
Advisory services relating to medical diagnostic products; advisory services relating to medical diagnostic productsmedical diagnostic products for extracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; Medical diagnostic testing services; medical diagnostic screening services in the field of diagnostic preparations
Publications
History of USPTO decisions and trademark events.
39 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2026
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
05/28/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/27/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/06/2025
IUCN
NOTICE OF ALLOWANCE CANCELLED
05/27/2025
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
05/27/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/26/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/15/2024
PUBO
PUBLISHED FOR OPPOSITION
10/15/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/12/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
09/12/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/12/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
09/12/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/09/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
06/11/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
06/11/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/12/2024
GNFR
FINAL REFUSAL E-MAILED
03/12/2024
CNFR
FINAL REFUSAL WRITTEN
03/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/12/2024
ALIE
ASSIGNED TO LIE
02/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/21/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
06/20/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
06/20/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/21/2023
GNRT
NON-FINAL ACTION E-MAILED
03/21/2023
CNRT
NON-FINAL ACTION WRITTEN
03/21/2023
DOCK
ASSIGNED TO EXAMINER
03/10/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/01/2022
NWAP
NEW APPLICATION ENTERED
05/28/2022
Continuous trademark protection
Get notified about every new filing that threatens INOVIQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.